NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Closed Posted
- Opportunity number
- PAR-20-218
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Originally
- Award size
- Up to $350,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Tribal Governments (Federally Recognized)
- Tribal Organizations (Not Federally Recognized)
- City/Township Governments
- Small Businesses
- 501(c)(3) Nonprofits
- For Profit Organizations
- State Governments
- Public or Indian Housing Auth.
- Special District Governments
- Independent School Districts
- Higher Education Inst. (Private)
- Other
- Non-501(c)(3) Nonprofits
- County Governments
- Higher Education Inst. (Public)
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to two years (R61 phase) of support for milestone-driven testing of bioavailability, pharmacokinetics, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design R33 studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combining the natural product with another treatment approach that is known to impact the same biological signature; or (3) studying the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or e
Files
| File | Type | Posted |
|---|---|---|
| PAR-20-218-Full-Announcement.html | HTML file | |
| PKG00261789-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity